https://www.selleckchem.com/products/benzylpenicillin-potassium.html Although combination of cyclin-dependent kinase 4 and 6(CDK4/6) inhibitors with endocrine therapy for advanced breast cancer (ABC) prolongs PFS in patients, but also has associated toxic side effects. However, few previous studies have summarized the toxic and side effects of CDK4/6 inhibitors. Therefore, this study summarized the corresponding toxic and side effects of CDK/6 inhibitors, which is of great importance for doctors and patients to understand how to balance the high survival rate brought by drugs with the decreased quality of life and improve the management of BC. PubMed, Embase, The Cochrane Library, and VIP databases were systematically searched to collect randomized controlled trials (RCTs) of CDK4/6 inhibitors combined with endocrine therapy for advanced breast cancer from January 2010 to December 2019.Two investigators independently reviewed the literatures. Before using the RevMan 5.3 software for a meta-analysis, date were extracted and the risk of bias with the include studies were asssurvival rate while reducing or even avoiding the side effects of CDK4/6Isis needed for better clinical management of BC. PROSPERO (CRD42020171112). PROSPERO (CRD42020171112). To evaluate the clinical performance of universal adhesives in etch-and-rinse or self-etch application modes through meta-analysis. A literature search was performed by two reviewers in the PubMed, Cochrane Library, and Embase databases (from January 2000 to March 2020). A total of 2,516 non-replicated records were identified and filtered. Studies that evaluated the clinical performance of universal adhesives using etch-and-rinse or self-etch mode were included. RevMan 5.3.5 (Cochrane, London, UK) was used to perform the meta-analysis. A total of 13 studies were included in the meta-analysis. The retention rates were higher in etch-and-rinse groups compared with self-etch groups [odds ratio (OR) =0.35, 95% confidence interval